PHAT Phathom Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1783183 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY86.8%
TTM net income YoY69.8%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin80.7%
Operating margin-9.3%
Net margin-30.2%
FCF margin-7.7%
EBITDA margin-9.1%
Returns
ROE—
ROA-28.4%
ROIC (approx.)—
Asset turnover0.94x
Leverage & solvency
Liabilities / assets200.8%
Debt / equity—
Current ratio1.76x
Interest coverage-0.41x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-21.3%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $84.72M | $74.27M | $58.30M | $57.58M | $49.50M | $39.50M | $28.52M | $29.66M |
| Cost of revenue | $18.37M | $15.10M | $12.00M | $7.65M | $6.19M | $5.04M | $3.72M | $3.81M |
| Gross profit | $66.36M | $59.18M | $46.30M | $49.94M | $43.31M | $34.47M | $24.80M | $25.85M |
| R&D expense | $8.74M | $7.81M | $7.77M | $7.49M | $7.03M | $9.08M | $9.18M | $8.58M |
| SG&A expense | $57.70M | $55.33M | $54.01M | $48.37M | $51.56M | $85.31M | $94.47M | $76.68M |
| Operating income | -$85,000 | -$3.96M | -$15.48M | -$5.93M | -$15.27M | -$59.92M | -$78.86M | -$59.42M |
| Interest expense | $15.39M | $15.10M | $15.80M | $16.42M | $16.11M | $17.52M | $18.07M | $18.59M |
| Net income | -$13.90M | -$17.58M | -$30.37M | -$21.15M | -$29.97M | -$75.81M | -$94.32M | -$74.45M |
| EBITDA | $35,000 | -$3.85M | -$15.37M | -$5.80M | -$15.12M | -$59.75M | -$78.69M | -$59.22M |
| EPS (basic) | -0.16 | -0.21 | -0.37 | — | -0.41 | -1.05 | -1.31 | — |
| EPS (diluted) | -0.16 | -0.21 | -0.37 | — | -0.41 | -1.05 | -1.31 | — |
| Weighted avg. shares (diluted) | 84.89M | 83.75M | 82.05M | — | 73.40M | 72.47M | 71.97M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $184.56M | $182.48M | $180.90M | $129.97M | $135.16M | $149.57M | $212.31M | $297.26M |
| Receivables | $107.60M | $97.42M | $80.72M | $78.13M | $55.79M | $51.26M | $36.36M | $38.80M |
| Inventory | $7.63M | $7.71M | $6.51M | $5.52M | $3.61M | $3.43M | $3.17M | $3.21M |
| Current assets | $308.01M | $295.92M | $276.57M | $228.97M | $207.78M | $218.88M | $264.90M | $360.13M |
| PP&E, net | $935,000 | $971,000 | $1.02M | $1.06M | $1.16M | $1.24M | $1.35M | $1.48M |
| Total assets | $345.02M | $327.07M | $305.12M | $259.15M | $240.29M | $250.22M | $294.21M | $378.32M |
| Current liabilities | $174.90M | $153.78M | $125.04M | $132.04M | $93.12M | $91.82M | $74.03M | $85.73M |
| Short-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term debt | $165.54M | $164.59M | $163.68M | $209.09M | $207.09M | $205.14M | $203.25M | $201.41M |
| Total debt | $165.54M | $164.59M | $163.68M | $209.09M | $207.09M | $205.14M | $203.25M | $201.41M |
| Total liabilities | $692.66M | $671.35M | $642.08M | $697.32M | $662.82M | $656.05M | $632.58M | $631.90M |
| Shareholders' equity | -$347.64M | -$344.27M | -$336.95M | -$438.17M | -$422.53M | -$405.83M | -$338.38M | -$253.58M |
| Net debt | -$19.02M | -$17.89M | -$17.23M | $79.11M | $71.94M | $55.57M | -$9.07M | -$95.85M |
| Shares outstanding | 81.22M | 80.07M | 79.44M | 71.42M | 71.04M | 70.10M | 69.64M | 68.52M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.84M | -$1.93M | -$15.65M | -$5.00M | -$14.12M | -$62.73M | -$84.93M | -$63.46M |
| Capital expenditure | $110,000 | $44,000 | $61,000 | $87,000 | $27,000 | $97,000 | $18,000 | $5,000 |
| Free cash flow | $1.73M | -$1.97M | -$15.71M | -$5.09M | -$14.14M | -$62.83M | -$84.95M | -$63.46M |
| Investing cash flow | -$110,000 | -$44,000 | -$61,000 | -$87,000 | -$27,000 | -$97,000 | -$18,000 | -$5,000 |
| Financing cash flow | $351,000 | $3.55M | $66.64M | -$97,000 | -$271,000 | $80,000 | $0 | $26.05M |
| Depreciation & amortization | $120,000 | $114,000 | $110,000 | $128,000 | $156,000 | $172,000 | $177,000 | $193,000 |
| Stock-based compensation | $5.92M | $6.71M | $5.53M | $5.61M | $9.30M | $8.27M | $5.54M | $6.69M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.